AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06396130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation by low level diode laser
Description: Diode laser exposure (Lite Medics 1.00-Watt serial number 148 Ver. SwvM. 150VS108VT.100) will be carried out using a continuous mode with 10 Hz frequency, 980 nm wavelength, and max power 15 WCW. The tip will be applied both at the buccal and the lingual side for 30 s each.
Study NCT06396130 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mock Laser Application
Description: Placebo for control group
Study NCT05042544 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of-Care Testing
Description: Participants will be offered finger-stick point-of-care testing for HCV
Study NCT04819191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHARING Choices
Description: SHARING Choices is a multicomponent communication intervention to proactively engage family members or friends and to support advance care planning in primary care
Study NCT04716049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Powerade©, CHP, CJ, FR, CWI
Description: Combination of recovery strategies including dietary, neuromuscular and physiological as follows:~Powerade©: players will drink 500 mL during the game~Carbohydrate and protein (CHP): players will drink 250 mL of water with CHP within 30 minutes after the end of the game.~Tart cherry concentrate (CJ): players will drink 30 mL of CJ within 30 minutes after the end of the game.~Foam roller (FR): players will follow FR protocol using a polyvinylchloride pipe roller. They will begin with the FR at the most proximal portion of the muscle and to roll as much body mass as tolerable back and forth at a cadence of 1 second superior and 1 second inferior for 45 seconds followed by a 15-second rest for each muscle group (quadriceps, adductors, hamstrings, abductors and calf) in each extremity and repeated once.~Cold Water Immersion (CWI): will be the last strategy used. Players will immerse their lower body to the level of hips for 10 minutes in cold water (13-14°C).
Study NCT04716049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Powerade©, CHP, STR, ICWI
Description: Combination of recovery strategies including dietary, neuromuscular and physiological as follows:~Powerade©: players will drink 500 mL of Powerade© during the game~Carbohydrate and protein intake (CHP): players will drink 250 mL of water with CHP within 30 minutes after the end of the competition.~Stretching (STR): players will perform 10-min of static stretching, involving 2 unilateral repetitions of 30 seconds held stretches to the quadriceps, adductors, hamstrings, abductors and calf muscles.~Intermittent Cold-Water Immersion (ICWI): will be the last strategy used. It will consist of five 2 min intermittent immersions of the lower limb (up to the iliac crest) in a cold-water bath (13-14ºC), separated by 2 min rest in ambient air. Ice will be added to the bath at regular intervals to maintain water temperature at 13-14ºC. Players will be instructed to stand in the bath, with as little movement as possible.
Study NCT05238558 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMPV-1
Description: Intradermal administration
Study NCT05238558 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF (as adjuvant)
Description: Intradermal administration
Study NCT05875012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: action observation physical training
Description: Action observation training 3 sessions per week for 3 successive months
Study NCT05875012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy training
Description: Traditional physical therapy training 3 sessions per week for 3 successive months
Study NCT04827173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcutaneous medium-frequency alternating current
Description: Patients receive nerve block of right forearm through transcutaneous medium-frequency alternating current
Study NCT04726436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dextrose 5% in water
Description: One hour before operation, patients were given dexrose 5%100/hour only for 2 hours to end at about middle of surgery
Study NCT04726436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dextrose 10%
Description: One hour before operation, patients were given dexrose 10 %100/hour only for 2 hours to end at about middle of surgery
Study NCT04726436 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: One hour before operation, patients were given normal saline100/hour only for 2 hours to end at about middle of surgery
Study NCT04808180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biorepair Shock Treatment
Description: Teeth from this group will undergo the application of Biorepair Toothpaste for the first 7 days of the month for 9 months (1 application per day that lasts 10 minutes).
Study NCT04808180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No treatment
Description: Teeth from this group will not be treated with the experimental toothpaste.
Study NCT05013099 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: zirconium Zr 89 crefmirlimab berdoxam
Description: Up to three zirconium Zr 89 crefmirlimab berdoxam PET scans (up to 1.0 mCi ± 20% at 1.5 mg API per scan, for a total of up to 3.0 mCi ± 20% and 4.5 mg API) as an IV infusion or slow bolus injection as follows: First (PETbaseline) within 14 days prior to the onset of IOT, and a second (PETEOC1) 4 to 6 weeks after start of immunotherapy. The second zirconium Zr 89 crefmirlimab berdoxam administration and scan (PETEOC1) should be completed prior to the start of the third cycle of IOT. Subjects who are determined by the treating physician to have PD on immunotherapy can receive the optional third zirconium Zr 89 crefmirlimab berdoxam PET scan at the principal investigator's (PI's) discretion.
Study NCT06228781 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous haemopoietic stem cell transplantation
Description: Immuno-ablation and autologous CD34 selected hematopoietic stem cell transplantation (HSCT).~Stem cell mobilization with cyclophosphamide 2g/m2 and filgrastim 10 ug/kg/d x 5 day.~Stem cell collection with cobe cpectra stem cell purification with Miltenyi CliniMACS Stem cell transplant conditioning with busulphan 3.2 mg/kg ; fludarabine 30mg/m2 or cladribine 10mg ；cytarabine 1-2g/m2 or idarubicin 8mg/m2；cyclophosphamide 40mg/kg followed by CD34 selected autologous hematopoietic stem cell transplant.
Study NCT05367362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocyclin
Description: 200 mg intravenous/oral minocycline hydrochloride for a total of 21 days
Study NCT06430814 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06287658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training on Kegel exercise and Ba Duan Jin applications online
Description: Kegel exercises and Ba Duan Jin applications online
Study NCT06287658 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: training on Kegel exercises and Ba Duan Jin applications after the research is completed
Description: Women in the control group will be given training on Kegel exercises and Ba Duan Jin applications after the research is completed.
Study NCT05657834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-TVB-2640
Description: 50 mg of TVB-2640 oral administration
Study NCT05614830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling ,
Description: The intervention group will receive sessions of dry needling to relief myofacial pain on trapezius
Study NCT05614830 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual physical therapy program
Description: Therapeutic exercise
Study NCT04604223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg
Description: Pioglitazone will be started at 45 mg/day dose for 10 days, after 10 days, the dose will be reduced to 30 mg/day to minimize possible adverse events. The treatment will be continued for 4 weeks (28 days) total
Study NCT04604223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone 45 mg
Description: Pioglitazone will be started at 45 mg/day dose for 10 days, after 10 days, the dose will be reduced to 30 mg/day to minimize possible adverse events. The treatment will be continued for 4 weeks (28 days) total
Study NCT05773482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing and Attention Training (BAT)
Description: BAT is an instructor guided breathing technique over 20 min that will be applied once in a training session and approximately one week later in a testing session.
Study NCT05773482 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathing Control
Description: Controlled Breathing (without mindfulness) is an instructor guided breathing technique over 20 min that will be applied once in a training session and approximately one week later in a testing session.
Study NCT05199129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1904-3
Description: Take once daily for 8 weeks orally
Study NCT05199129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCP1904-3
Description: Take once daily for 8 weeks orally
Study NCT05199129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2001-1
Description: Take once daily for 8 weeks orally
Study NCT05199129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD2001-1
Description: Take once daily for 8 weeks orally
Study NCT04625088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized liquid test meal
Description: During this study visit, a standardized liquid test meal will be administered. Blood samples will be collected at baseline and then every 30 minutes for 4 hours after test meal.
Study NCT04625088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine + Standardized liquid test meal
Description: During this study visit, 1.0 mg atropine will be administered I.V and then a standardized liquid test meal will be administered. Blood samples will be collected at baseline, following atropine administration, and then every 30 minutes for 4 hours after test meal.
Study NCT06198894 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: steroid-eluting sinus stent implant
Description: In-office bilateral placement of the steroid-eluting sinus stent in the ethmoid sinuses under local anesthesia
Study NCT06198894 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Systemic glucocorticoids
Description: Groups were given oral methylprednisolone (32 mg/d on days 1-5; 16 mg/d on days 6-10; and 8 mg/d on days 11-20),
Study NCT06198894 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: saline irrigations
Description: Patients were routinely treated with saline irrigations (250ml) twice daily
Study NCT06198894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline irrigations
Description: Patients were routinely treated with saline irrigations (250ml) twice daily
Study NCT06198894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Groups were given systemic glucocorticoid placebo
Study NCT06198894 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham procedure
Description: The sham procedure was performed in-office under local anesthesia
Study NCT05517044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nitrogen tent preacclimatization to high altitude
Description: The participants assigned to the preacclimatization group spend a minimum of six hours during sleep, throughout the acclimatization period (four weeks preceding the expedition) in a nitrogen concentration tent (Hypoxico OHG, Traunstein, Germany) set to an environmental PO2 corresponding to an altitude of 2500 masl, with a progression to 5500 masl within 28 days in steps of 1000 m every seven days. Respiratory Polygraphy is used to detect periodic breathing, SpO2, and heart rate continuously during sleep and is performed before and after the designated preacclimatization period, and repetitively when increasing normobaric hypoxia in the group with nitrogen concentration tent preacclimatization.
Study NCT04849598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Description: Oxygen therapy during ESWTs and Stair Walking Test: one test using the prescribed constant oxygen flow and one using an automatic oxygen titration system. SpO2 target range: 90 - 94%
Study NCT06124560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
Description: The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
Study NCT05609136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bobath+Scapular Stabilization Exercises
Description: Scapular stabilization exercises will be given to patients in addition to Bobath therapy. It will be applied with the patient in a sitting position, with the shoulder at 90 degrees and the elbow extended. The patient will be given exercises with isometric contraction while the shoulder is in protraction and retraction by the physiotherapist. Isometric contraction will last for 5 seconds and each exercise will be repeated 2x15 times. There will be a 1-minute rest period between sets. The exercises will be performed in 2 different positions, in the flexion position and in the diagonal position.
Study NCT05609136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bobath+Scapular Stabilization Exercises
Description: Scapular stabilization exercises will be given to patients in addition to Bobath therapy. It will be applied with the patient in a sitting position, with the shoulder at 90 degrees and the elbow extended. The patient will be given exercises with isometric contraction while the shoulder is in protraction and retraction by the physiotherapist. Isometric contraction will last for 5 seconds and each exercise will be repeated 2x15 times. There will be a 1-minute rest period between sets. The exercises will be performed in 2 different positions, in the flexion position and in the diagonal position.
Study NCT05530421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
Study NCT05530421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
Study NCT05530421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
Study NCT06392620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Group
Description: n individually planned exercise program including stretching, strengthening, respiratory, aerobic and posture exercises will be applied via video conference method
Study NCT06021145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 26-week use of automated insulin delivery system with empagliflozin (2.5 mg daily) in individuals with suboptimal time in range.
Study NCT06021145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 26-week use of automated insulin delivery system with placebo (daily) in individuals with suboptimal time in range.
Study NCT05732688 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Image-based ex-vivo drug screening platform (pharmacoscopy)
Description: Leukemic cells from a patient at relapse can be screened for sensitivity to single compounds. A drug score is calculated for each compound (defined as 1 - (% target cells in drug treated conditions / % target cells under control condition)). If a drug kills all target cells specifically, the best possible score is 1. If the drug is killing all non-target cells, the score goes to negative infinite. If a drug kills both target and non-target cell populations equally, or does nothing, the score is 0.
Study NCT04696315 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multiple features extraction
Description: In the present study, the gold standard of preclinical AD is amyloid PET. SCD with positive amyloid is the target population for early AD intervention. The investigators aim to extract the diagnostic features from multiple parameter MRI, genetic, blood and clinical data using Max-Relevance and Min-Redundancy (mRMR) algorithm. Then, based on support vector machine (SVM), random forest (RF) and multi-kernel learning (MKL) classification methods, the investigators will construct predicted diagnostic model of preclinical AD.
Study NCT03930277 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalogram
Description: Electroencephalogram for fetal brain activity monitoring.
Study NCT05365178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3616 capsule
Description: TQB3616 capsule is a CDK (cyclin-dependent kinases) 4/6 kinase inhibitor, which can selectively inhibit THE activity of CDK4/6 kinase, make it form a complex with Cyclin D, reduce the phosphorylation level of retinoblastoma protein (Rb) in cancer cells, and prevent cells from entering S phase from G1 phase
Study NCT05365178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is a placebo
Study NCT05365178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant injection
Description: Fulvestrant is a competitive estrogen receptor antagonist, and its mechanism is related to the down-regulation of estrogen receptor (ER) protein level
Study NCT05365178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant injection
Description: Fulvestrant is a competitive estrogen receptor antagonist, and its mechanism is related to the down-regulation of estrogen receptor (ER) protein level
Study NCT05395728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deflate the tracheostomy cuff early
Description: The tracheostomy cuff will be early deflated, on beginning the weaning mechanical ventilation
Study NCT05395728 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deflate the tracheostomy cuff after complete weaning mechanical ventilation
Description: The tracheostomy cuff will be deflated onl twenty four hours after complete weaning mechanical ventilation
Study NCT03743298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-MEL-1
Description: AV-MEL-1: Autologous dendritic cells loaded with autologous tumor antigens (ATA) from a short-term cell culture of autologous tumor cells. AV-MEL-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
Study NCT05354869 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urostym
Description: electric pelvic floor muscle stimulator
Study NCT05354869 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: patient education on home exercises and stretching
Study NCT05570357 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Berberine+Cinnamon (TDS)
Description: The supplements contains 400 mg Berberine, and 200 mg Cinnamon extract
Study NCT05570357 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (TDS)
Description: Placebo contains Maltodexterin
Study NCT05179057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posoleucel
Description: Administered as 2-4 milliliter infusion, visually identical to placebo
Study NCT05179057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as 2-4 milliliter infusion, visually identical to Posoleucel
Study NCT05073224 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Active Straight Leg Raise Test
Description: The ASLR test is a well-established clinical test that assesses stability of the lumbar spine/pelvis, posterior pelvic pain severity, and ability to activate the abdominal muscles. It is performed in supine. Participants are instructed to raise one leg, with the knee straight, to a heel height of 20 cm. The leg is held at the top for 5 seconds, then slowly lowered to the ground. The participant is asked to report perceived difficulty to raise the leg on a 0 to 5 scale (0=not at all difficult; 5=unable to lift leg) and pain on a 0 to 10 scale (0=no pain; 10=worst possible pain). If difficulty or pain are rated at a 1 or higher, the test is repeated with the researcher providing external compression of the pelvis. If perceived difficulty or reported pain are lower with compression, the test is considered positive for lumbopelvic instability. The test is then repeated on the opposite limb.
Study NCT05073224 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Active Straight Leg Raise Test
Description: The ASLR test is a well-established clinical test that assesses stability of the lumbar spine/pelvis, posterior pelvic pain severity, and ability to activate the abdominal muscles. It is performed in supine. Participants are instructed to raise one leg, with the knee straight, to a heel height of 20 cm. The leg is held at the top for 5 seconds, then slowly lowered to the ground. The participant is asked to report perceived difficulty to raise the leg on a 0 to 5 scale (0=not at all difficult; 5=unable to lift leg) and pain on a 0 to 10 scale (0=no pain; 10=worst possible pain). If difficulty or pain are rated at a 1 or higher, the test is repeated with the researcher providing external compression of the pelvis. If perceived difficulty or reported pain are lower with compression, the test is considered positive for lumbopelvic instability. The test is then repeated on the opposite limb.